Caitong International Asset Management’s Summit Therapeutics SMMT Stock Holding History

Caitong International Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$80.7K	Buy	+5,536	New	+$98.2K	0.01%	606

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Caitong International Asset Management's SMMT Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 5,536 shares worth $80.7K. The stake represents 0.01% of the portfolio and ranks #606 among its holdings.

242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Caitong International Asset Management held 5,536 shares of Summit Therapeutics worth $80.7K as of Q2 2026.
Summit Therapeutics was a new Caitong International Asset Management position in Q2 2026.
Summit Therapeutics made up 0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #606 holding.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.